Christopher Horan Joins Dermira as Chief Technical Operations Officer
April 19 2018 - 4:04PM
Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated
to bringing biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of patients living
with chronic skin conditions, today announced the appointment of
Christopher Horan as Chief Technical Operations Officer. In this
newly created role, Chris will oversee pharmaceutical sciences,
procurement, supply chain, including contract manufacturing, and
quality as Dermira prepares to commercialize glycopyrronium
tosylate (formerly DRM04), for which a New Drug Application is
under review by the U.S. Food and Drug Administration (FDA) for the
treatment of primary axillary hyperhidrosis (excessive underarm
sweating beyond what is needed for normal body temperature
regulation), and advance the development of lebrikizumab, currently
being studied in Phase 2b for the treatment of moderate-to-severe
atopic dermatitis.
“Chris brings a wealth of technical operations experience to
Dermira and we are delighted that he is joining at a critical
moment for the company as we prepare to bring our first treatment
to patients,” said Tom Wiggans, chairman and chief executive
officer of Dermira. “His broad experience managing external
manufacturing and supply chain will ensure that we drive the
operational excellence necessary to reliably deliver high-quality
products to people living with skin conditions.”
Chris joins Dermira from Genentech where he spent nearly 14
years in roles of increasing responsibility within its Operational
Excellence, Supply Chain, Procurement and Technical Operations
functions. He most recently served as Senior Vice President, Global
Product and Supply Chain Management at Genentech (a member of the
Roche Group), where he led a team supplying all Roche biopharma
products worldwide. Prior to Genentech, he worked for Merck &
Company in global roles across Engineering, Manufacturing and
Operational Excellence.
“I am thrilled to be joining Dermira at a pivotal moment for the
company as we continue to develop our manufacturing and supply
chain capabilities in preparation for the potential launch of
glycopyrronium tosylate,” said Horan. “Dermira’s patient-centered,
science-driven culture is a great fit and strong attraction for me.
I look forward to contributing to the company’s commercial
success.”
Chris, who holds a BE in Engineering from the Stevens Institute
of Technology, will serve on the executive management committee.
About DermiraDermira is a
biopharmaceutical company dedicated to bringing biotech ingenuity
to medical dermatology by delivering differentiated, new therapies
to the millions of patients living with chronic skin
conditions. Dermira is committed to understanding the
needs of both patients and physicians and using its insight to
identify and develop leading-edge medical dermatology programs.
Dermira’s pipeline includes two late-stage product candidates that
could have a profound impact on the lives of patients:
glycopyrronium tosylate (formerly DRM04), for which a New Drug
Application is under review by the U.S. Food and Drug
Administration for the treatment of primary axillary hyperhidrosis
(excessive underarm sweating beyond what is needed for normal body
temperature regulation), and lebrikizumab, in Phase 2b development
for the treatment of moderate-to-severe atopic dermatitis.
Dermira is headquartered in Menlo Park,
Calif. For more information, please
visit http://www.dermira.com. Follow Dermira on Twitter
and LinkedIn.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website (www.dermira.com),
LinkedIn page (https://www.linkedin.com/company/dermira-inc-) and
corporate Twitter account (@DermiraInc) as channels of distribution
of information about its company, product candidates, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Dermira may use these
channels to comply with its disclosure obligations under Regulation
FD. Therefore, investors should monitor Dermira’s website, LinkedIn
page and Twitter account in addition to following
its SEC filings, news releases, public conference calls
and webcasts.
Forward-Looking Statements The information in
this news release contains forward-looking statements and
information within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, which are subject to the “safe harbor” created
by those sections. This news release contains forward-looking
statements that involve substantial risks and uncertainties,
including statements with respect to potential FDA approval of
glycopyrronium tosylate for the treatment of primary axillary
hyperhidrosis; the advancement of development of lebrikizumab for
the treatment of moderate-to-severe atopic dermatitis;
commercialization of Dermira’s product candidates; Dermira’s
ability to reliably deliver high-quality products to people living
with skin conditions; Dermira’s plans to develop its manufacturing
and supply chain capabilities; and Dermira’s anticipated commercial
efforts and successes. These statements deal with future events and
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be
materially different from the information expressed or implied by
these forward-looking statements. Factors that could cause actual
results to differ materially include risks and uncertainties such
as those relating to the design, implementation and outcomes of
Dermira’s clinical trials; the outcomes of Dermira’s future
meetings with regulatory agencies; Dermira’s dependence on
third-party clinical research organizations, manufacturers and
suppliers; Dermira’s ability to attract and retain key employees;
Dermira’s ability to obtain necessary additional capital; and
Dermira’s ability to continue to stay in compliance with applicable
laws and regulations. You should refer to the section entitled
“Risk Factors” set forth in Dermira’s Annual Report on Form 10-K,
Dermira’s Quarterly Reports on Form 10-Q and other filings Dermira
makes with the SEC from time to time for a discussion of important
factors that may cause actual results to differ materially from
those expressed or implied by Dermira’s forward-looking statements.
Furthermore, such forward-looking statements speak only as of the
date of this news release. Dermira undertake no obligation to
publicly update any forward-looking statements or reasons why
actual results might differ, whether as a result of new
information, future events or otherwise, except as required by
law.
Contacts:
Media:Erica JeffersonVice President, Corporate
Communications650-421-7216media@dermira.com
Investors:Ian Clements, Ph.D.Vice President, Investor
Relations650-422-7753investor@dermira.com
Robert H. Uhl Westwicke PartnersManaging
Director858-356-5932robert.uhl@westwicke.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Apr 2023 to Apr 2024